Overview

Single Ascending Dose Study of NH102 in Healthy Subjects

Status:
Recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety, tolerability and pharmacokinetics (PK) of NH102 when administered as single oral dose at escalating dose levels in healthy participants.
Phase:
Phase 1
Details
Lead Sponsor:
Jiangsu Nhwa Pharmaceutical Co., Ltd.